According to Cancer Research UK, global cancer incidence is predicted to increase by 28 million new cases annually by 2040. Yet, despite major advances in oncology, many patients remain resistant to current treatments.

Eidolon Therapeutics, currently based at the Institute of Cancer Research and Imperial College London, brings together scientists and innovators dedicated to transforming immunotherapy. Our mission is to develop precise and effective treatments that target diverse cancer types and stages, overcoming resistance and offering new hope to patients who do not respond to existing therapies.